A Study of LY3090106 in Japanese and Caucasian Healthy Participants
Status: | Active, not recruiting |
---|---|
Conditions: | Healthy Studies |
Therapuetic Areas: | Other |
Healthy: | No |
Age Range: | 20 - 64 |
Updated: | 4/6/2019 |
Start Date: | November 19, 2018 |
End Date: | April 12, 2019 |
A Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3090106 in Japanese and Caucasian Healthy Subjects
The main purpose of this study is to evaluate the safety of a study drug known as LY3090106
in healthy Caucasian and Japanese participants. Side effects and tolerability will be
documented. Blood samples will be taken to compare how the body handles the drug. The study
will last about 12 weeks, not including screening or additional follow-up.
in healthy Caucasian and Japanese participants. Side effects and tolerability will be
documented. Blood samples will be taken to compare how the body handles the drug. The study
will last about 12 weeks, not including screening or additional follow-up.
Inclusion Criteria:
- Overtly healthy Japanese or Caucasian
- Body mass index (BMI) 18.0 - 32.0 kilograms per square meter (kg/m²)
Exclusion Criteria:
- Have participated, within the last 30 days, in a clinical study involving an
investigational product (IP). If the previous IP has a long half-life, 5 half-lives or
30 days (whichever is longer) should have passed
- Have had symptomatic herpes zoster within 3 months of screening
- Show evidence of active or latent tuberculosis (TB)
- Have known hypogammaglobulinemia or a screening serum immunoglobulin (Ig) G <565
milligrams per deciliter (mg/dL)
- Have received live or attenuated vaccine(s) within 1 month of screening, or intend to
during the study
- Are immunocompromised
- Have received treatment with biologic agents (such as monoclonal antibodies, including
marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing.
Participants with any prior exposure to ixekizumab, tabalumab or other biologic agents
directly targeting Interleukin 17 (IL-17) and/or B cells (e.g., rituximab, belimumab,
etc.) are excluded
We found this trial at
1
site
1085 N Harbor Blvd
Anaheim, California 92801
Anaheim, California 92801
(714) 774-7777
Principal Investigator: Peter J Winkle
Phone: 714-774-7777
Anaheim Clinical Trials, LLC Anaheim Clinical Trials (ACT) is a research center of excellence for...
Click here to add this to my saved trials